HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Organic program

This article was originally published in The Rose Sheet

Executive Summary

USDA Agricultural Marketing Service and National Organic Program officials met with the National Organic Standards Board and the Organic Trade Association June 9 to discuss issues relating to a guidance that declared personal care cannot be certified under NOP. Guidance was released in April but was subsequently retracted by AMS under pressure from industry and Congress; however, agency maintains NOP never applied to personal care products (1"The Rose Sheet" May 10, 2004, p. 9). June 9 meeting was intended to prompt "constructive action on future policies for the organic industry," trade group says, and was held at the request of Department of Agriculture Secretary Ann Veneman, who instructed AMS to work with the advisory board and industry on NOP issues (2"The Rose Sheet" May 31, 2004, p. 5)...

You may also be interested in...



USDA Organic Guidance Excluding Cosmetics From Certification Retracted

The USDA Agricultural Marketing Service retracted a recent statement clarifying that personal care and other products cannot be certified under the National Organic Program, according to the agency

Fujifilm Demonstrates Health Specialism With European HealthTech Spinout

From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics. 

Financing Quarterly Statistics, Q1 2024

During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel